IGC PHARMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease. Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What to […]
ACADIA RADIANT (Alzheimer’s Disease Psychosis) In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis. Inclusion Criteria: 50 years to 95 years of age Meets clinical criteria for possible or probable Alzheimer’s Disease Psychotic symptoms (hallucinations or delusions) for at least 2 months Availability of a designated study partner/caregiver What to Expect
SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria: 50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study
SUVEN CTP3S1502HT6 Read More »
ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria: 50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
